Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.
Biomira Inc, following its acquisition of ProlX Pharmaceutical Corp, is developing PX-12, an inhibitor of thioredoxin, for the potential treatment of cancer. PX-12 has completed phase I clinical trials.